ERBB2 and breast cancer: In a study conducted by Cortés et al., 29 patients with HER2-positive breast cancer whose disease progressed during prior trastuzumab-based therapy received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) until progressive disease or unacceptable toxicity (Cortés et al., 2012).